Trandolapril hydrochloride
Trandolapril (RU44570) hydrochloride is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolapril hydrochlorideat. Trandolapril hydrochloride is an orally active angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI).
For research use only. We do not sell to patients.
- CAS No.: 87725-72-2
- Formula: C24H35ClN2O5
- Molecular Weight:467.00
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Target: Angiotensin-converting Enzyme (ACE)[1]
Trandolapril hydrochloride (0.3 mg/kg/day; p.o.; 4 weeks) improves arterial mechanics in rats, prevents arterial hypertrophy, collagen and cellular fibronectin accumulation[3].
randolapril (0.3 mg/kg/day; p.o.; 4 months) exhibits a chronic anti-hypertension effects in rats, results in blood pressure decreasing[3].
Trandolapril hydrochloride (0.25 mg/kg; p.o.; twice a day; 4 months) inhibits Atherosclerosis in the Watanabe Heritable Hyperlipidemic Rabbit[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:UUD (unilateral ureteral obstruction) model in Male CD-1 mice (18-22 g)[2]
-
Dosage:3 mg/kg
-
Administration:Oral gavage; daily, for 7 days
-
Result:Resulted in renal interstitial matrix expression (including fibronectin, type I, and type III collagen) decreasing, and inhibited myofibroblast activation by surprising a-smooth muscle actin (a-SMA) expression, decreased the RANTES (regulated on activation, normal T cell expressed and secreted) and TNF-α level.
-
Animal Model:SHR model (spontaneously hypertensive rats, 4-week-old)[3]
-
Dosage:0.3 mg/kg
-
Administration:Oral gavage; daily for 4 weeks
-
Result:Reduced collagen content in the aortic media and increased ariterial distensibility up to about 80%.
-
Animal Model:Watanabe heritable hyperlipidemic rabbit (3 months old)[4]
-
Dosage:0.25 mg/kg
-
Administration:Oral gavage; twice a day; 9 months
-
Result:Decreased in atherosclerotic involvement of the intimal surface, and also decreased cholesterol content in descending thoracic aorta.
Chemical Information
-
CAS No. 87725-72-2
-
Molecular Weight 467.00
-
Formula C24H35ClN2O5
-
SMILES
O=C([C@H]1N(C([C@@H](N[C@H](C(OCC)=O)CCC2=CC=CC=C2)C)=O)[C@@]3([H])CCCC[C@]3([H])C1)O.Cl
-
Synonyms
RU44570 hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Peters DC, et al. Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders. Drugs. 1998 Nov;56(5):871-93. [Content Brief]
[2]. Tan X, et al. Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy. Kidney Int. 2009 Dec;76(12):1248-57. [Content Brief]
[3]. Koffi I, et al. Prevention of arterial structural alterations with verapamil and trandolapril and consequences for mechanical properties in spontaneously hypertensive rats. Eur J Pharmacol. 1998 Nov 13;361(1):51-60. [Content Brief]
[4]. Chobanian AV, et al. Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1992 Oct;20(4):473-7. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Trandolapril hydrochloride Related Classifications
HY-B0592A Related Classifications
Powered by Bioz
- Trandolapril
- 87725-72-2
- RU44570
- RU 44570
- RU-44570
- Angiotensin-converting Enzyme (ACE)
- congestive heart failure
- CHF
- myocardial infarction
- MI
- Trandolapril hydrochlorideat
- orally active
- hypertension
- nonsulfhydryl
- arterial hypertrophy
- collagen
- cellular fibronectin accumulation
- spontaneously hypertensive rats
- UUD model
- unilateral ureteral obstruction
- UUO model
- Inhibitor
- inhibitor
- inhibit